J T Merrill

Summary

Publications

  1. pmc TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus
    Chang Hee Suh
    Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Arthritis Res Ther 12:R146. 2010
  2. ncbi request reprint Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein
    J T Merrill
    Division of Rheumatology, St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    Thromb Haemost 81:748-57. 1999
  3. doi request reprint Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
    Joan T Merrill
    Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
    Ann Rheum Dis 70:1905-13. 2011
  4. doi request reprint Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
    Jt Merrill
    Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Lupus 20:709-16. 2011
  5. doi request reprint Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    Joan T Merrill
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Arthritis Rheum 62:222-33. 2010
  6. ncbi request reprint Antiphospholipid syndrome: what's new in understanding antiphospholipid antibody-related stroke?
    Joan T Merrill
    Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 8:159-61. 2006
  7. ncbi request reprint Do antiphospholipid antibodies develop for a purpose?
    Joan T Merrill
    Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 8:109-13. 2006
  8. pmc A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus
    S Wang
    Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
    Genes Immun 13:380-7. 2012
  9. pmc Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis
    C P Lin
    Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Genes Immun 13:232-8. 2012
  10. ncbi request reprint What causes the antiphospholipid syndrome?
    J T Merrill
    Division of Rheumatology, St Luke s Roosevelt Hospital Center, 432 West 58th Street, Antenucci Building, New York, NY 10019, USA
    Curr Rheumatol Rep 3:293-300. 2001

Detail Information

Publications32

  1. pmc TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus
    Chang Hee Suh
    Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Arthritis Res Ther 12:R146. 2010
    ..In animal models, absence of TAM kinases is associated with lupus-like disease. To test whether human systemic lupus erythematosus (SLE) patients might have deficient levels of TAM ligands, we measured Gas 6 and protein S levels in SLE...
  2. ncbi request reprint Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein
    J T Merrill
    Division of Rheumatology, St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    Thromb Haemost 81:748-57. 1999
    ..Antiphospholipid (anti-beta2-glycoprotein I) antibodies might cause sporadic thrombosis, at least in part, by impairing this novel regulatory mechanism...
  3. doi request reprint Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
    Joan T Merrill
    Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
    Ann Rheum Dis 70:1905-13. 2011
    ..Type I interferons (IFNs) appear to play a central role in disease pathogenesis in systemic lupus erythematosus (SLE), making them potential therapeutic targets...
  4. doi request reprint Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
    Jt Merrill
    Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Lupus 20:709-16. 2011
    ..204). This post hoc analysis evaluates the hypothesis that assessment of BILAG A flares may distinguish potential treatment effects with greater sensitivity than assessment of BILAG B flares...
  5. doi request reprint Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    Joan T Merrill
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Arthritis Rheum 62:222-33. 2010
    ..The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately-to-severely active extrarenal SLE...
  6. ncbi request reprint Antiphospholipid syndrome: what's new in understanding antiphospholipid antibody-related stroke?
    Joan T Merrill
    Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 8:159-61. 2006
  7. ncbi request reprint Do antiphospholipid antibodies develop for a purpose?
    Joan T Merrill
    Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 8:109-13. 2006
    ....
  8. pmc A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus
    S Wang
    Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
    Genes Immun 13:380-7. 2012
    ..0004) and UBCH7 protein expression (P=0.0068). The results suggest that variants carried on the SLE-associated UBE2L3 risk haplotype influence autoimmunity by modulating UBCH7 expression...
  9. pmc Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis
    C P Lin
    Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Genes Immun 13:232-8. 2012
    ..This study provides the first investigation of MYH9 in LN in non-Africans and of APOL1 in LN in any population, and presents novel insight into the potential role of MYH9 in LN in EAs...
  10. ncbi request reprint What causes the antiphospholipid syndrome?
    J T Merrill
    Division of Rheumatology, St Luke s Roosevelt Hospital Center, 432 West 58th Street, Antenucci Building, New York, NY 10019, USA
    Curr Rheumatol Rep 3:293-300. 2001
    ..Thus, normally cryptic, functionally important epitopes of phospholipid-binding proteins are subjected to increased exposure to immune surveillance...
  11. pmc Genetic associations of LYN with systemic lupus erythematosus
    R Lu
    Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
    Genes Immun 10:397-403. 2009
    ..These results support an association of LYN with European-derived individuals with SLE, especially within autoantibody or clinical subsets...
  12. ncbi request reprint Which antiphospholipid antibody tests are most useful?
    J T Merrill
    Division of Rheumatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Rheum Dis Clin North Am 27:525-49. 2001
    ..slrapls.org, www.hematology.org, www.acforum.org, www.americanheart.org, www.rarediseases.org, www.aarda.org, and www.lupus.org...
  13. ncbi request reprint Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
    J A James
    Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Lupus 16:401-9. 2007
    ..A prospective, blinded trial testing the capacity of hydroxychloroquine to delay or prevent SLE in high risk populations is warranted...
  14. pmc Evaluation of C1q genomic region in minority racial groups of lupus
    B Namjou
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Genes Immun 10:517-24. 2009
    ..Further studies with higher SNP densities in this region and other complement components are necessary to elucidate the complex genetics and phenotypic interactions between complement components and SLE...
  15. ncbi request reprint Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome
    D Erkan
    Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA
    Lupus 11:215-20. 2002
    ..These associations were not found with antiprothrombin antibodies. In conclusion dual autoantibodies to beta2GPI and protein S are associated with increased history of thrombosis in the antiphospholipid syndrome...
  16. pmc Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population
    L Guo
    Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Genes Immun 10:531-8. 2009
    ..Our results suggest that BANK1 polymorphisms alter immune system development and function to increase the risk for developing lupus...
  17. ncbi request reprint Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus
    J T Merrill
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Lupus 13:869-76. 2004
    ..This would allow manifestations of fullblown APS an appropriate impact towards the diagnosis of SLE without leading to a premature diagnosis of SLE for people who might better be considered to have moderate to severe primary APS...
  18. doi request reprint Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity
    A Ippolito
    Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
    Lupus 20:250-5. 2011
    ..Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials...
  19. doi request reprint The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
    J T Merrill
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Arthritis Rheum 62:3077-87. 2010
    ..To evaluate abatacept therapy in patients with non-life-threatening systemic lupus erythematosus (SLE) and polyarthritis, discoid lesions, or pleuritis and/or pericarditis...
  20. pmc Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort
    B Namjou
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Genes Immun 12:270-9. 2011
    ..99E-13, OR=5.2, 95% CI=3.18-8.56). Our data confirm and expand previous reports and provide additional support for the involvement of TREX1 in lupus pathogenesis...
  21. doi request reprint Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans
    J A Kelly
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Genes Immun 9:187-94. 2008
    ..We conclude that genetic variants of IRF5 associate with SLE in multiple populations, providing evidence that IRF5 is likely to be a crucial component in SLE pathogenesis among multiple ethnic groups...
  22. ncbi request reprint LJP 1082: a toleragen for Hughes syndrome
    J T Merrill
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Lupus 13:335-8. 2004
    ..Issues of antigenic selection and multiplex forces influencing tolerance and immunity may have impact on its optimal development and use in patients...
  23. ncbi request reprint BLyS antagonists and peptide tolerance induction
    J T Merrill
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Lupus 14:204-9. 2005
    ..Specific development programs are ongoing using both of these strategies and have recently entered human trials...
  24. pmc Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome
    Sudha Visvanathan
    University of California at Los Angeles, 90095, USA
    Arthritis Rheum 48:737-45. 2003
    ..To test the feasibility of applying a mimetic (specific for a patient-derived prothrombotic anticardiolipin antibody [aCL]) to study the homologous, disease-associated aCL in patients with antiphospholipid syndrome (APS)...
  25. ncbi request reprint Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance
    Maria Laura Bertolaccini
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London, UK
    Thromb Haemost 90:636-41. 2003
    ..136% [60-174] in controls). Anti-ProtS are frequent in SLE patients with thrombosis and pregnancy morbidity. These antibodies do not interfere with free protein S in plasma since its level and/or functional activity are not impaired...
  26. ncbi request reprint The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis
    Ewa Olech
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 8:100-8. 2006
    ..Higher 17beta-estradiol levels were observed in aCL antibody-positive RA patients than in aCL antibody-negative patients and especially in premenopausal women, which may predispose to a more efficient immune response...
  27. ncbi request reprint The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis
    Joan T Merrill
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 5:401-6. 2003
    ....
  28. ncbi request reprint Diagnosis of the antiphospholipid syndrome: how far to go?
    Joan T Merrill
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th St, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 6:469-72. 2004
    ..The antiphospholipid syndrome (APS) is a complex hypercoagulable disorder that as yet defies the possibility of simple, predictive testing...
  29. ncbi request reprint Genetics of antiphospholipid syndrome
    Tetsuya Horita
    Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
    Curr Rheumatol Rep 6:458-62. 2004
    ..Genome-wide linkage analysis and larger cohort studies would lead to better understanding of the genes that might be involved in APS...
  30. ncbi request reprint Catastrophic antiphospholipid syndrome
    Joan T Merrill
    University of Oklahoma, USA
    Nat Clin Pract Rheumatol 2:81-9. 2006
    ....
  31. pmc IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome
    Daniel Lopez
    Corgenix Inc, 12061 Tejon St, Westminster, CO 80234, USA
    Clin Dev Immunol 10:203-11. 2003
    ..These results suggest that autoantibodies against beta2GPI/oxLDL complexes are etiologically important in the development of atherosclerosis in APS...
  32. ncbi request reprint Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome
    Luis R Lopez
    Corgenix, 12061 Tejon St, Westminster, CO 80234, USA
    Am J Clin Pathol 121:142-9. 2004
    ..These results suggest an important pathogenic role of anti-B2GPI antibodies in arterial thrombosis. In addition, anti-B2GPI and aPS antibodies seem to provide the best diagnostic value for the laboratory assessment of APS...